Jasper Therapeutics logo

Jasper Therapeutics(NASDAQ) JSPR

Market Cap$18.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 Year-99%
1 Year-77%
1 Month-21%
$0.57
+1.98%
+0.01Today
Jasper Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.562026-10-06
Jasper Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.44%USD 0.632026-09-29
1 month-20.96%USD 0.712026-09-04
3 month+8.84%USD 0.512026-07-08
Year to date-69.39%USD 1.832025-12-31
1 year-76.66%USD 2.402025-10-06
3 year-93%USD 8.002023-10-06
5 year-99.33%USD 83.202021-10-07
Since inception-99.43%USD 98.202020-01-10

Jasper Therapeutics Financials at a Glance

Market Cap

$18.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$31.77M

EPS (TTM)

-$1.58

P/E Ratio

-0.35

Dividend

$0.00

Beta (Volatility)

1.02 (Average)

Price

$0.57

Volume

230,743.56

Open

$0.54

Previous Close

$0.56

Daily Range

$0.54 - $0.59

52-Week Range

$0.32 - $2.69

Estimated Earnings Date

Nov 9, 2026

JSPR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Jasper Therapeutics

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for mast and hematopoietic stem cell-driven diseases. The company’s lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor signaling, targeting various mast cell-driven diseases.

Products and Services
  • Briquilimab for chronic spontaneous urticaria and asthma
  • Therapeutics for sickle cell disease and Fanconi anemia
  • Conditioning agents for stem cell transplants
Growth Outlook
  • Strong pipeline targeting significant unmet medical needs
  • Potential for market expansion in mast cell-driven diseases
  • Focus on advancing clinical trials to attract partnerships
Financial Highlights
  • Recent quarterly net income of -$2.76 million
  • Cash and cash equivalents of $7.31 million as of June 30, 2026
  • Trailing twelve months (TTM) cash flow from operations of -$69.19 million
Jasper Therapeutics, Inc. operates in the biotechnology sector, emphasizing innovative solutions for serious health conditions. The company is actively developing briquilimab, which has the potential to address significant health challenges associated with mast cell-driven diseases. The focus on clinical trials and partnerships may enhance growth prospects, particularly as the market for these therapeutics expands. Financially, the company has faced challenges, with recent quarterly losses and a notable cash burn rate. However, the existing cash reserves provide a foundation for ongoing research and development efforts. Investors may find Jasper Therapeutics an intriguing opportunity within the biotechnology landscape, given its specialized focus and potential for future growth.
AI Generated • Sep 18, 2026

Industry

Biotechnology

Sector

Health Care

Employees

25

CEO

Jeet Mahal, MBA

Website

www.jaspertherapeutics.com

Headquarters

Redwood City, CA 94065, US

JSPR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-618.87%

Return on Capital

-1494.95%

Return on Assets

-269.20%

Earnings Yield

-2.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$18.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

33.27M

Volume

230.74K

Avg. Volume

1.36M

Financials (TTM)

Gross Profit

-$21.00K

Operating Income

-$55.16M

EBITDA

-$31.23M

Operating Cash Flow

-$60.33M

Capital Expenditure

$0.00

Free Cash Flow

-$60.33M

Cash & ST Invst.

$7.31M

Total Debt

$270.00K

Jasper Therapeutics Performance Analysis

Jasper Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Jasper Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Jasper Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -10.33-61.6%
20232023-12-31USD -6.18-40.2%
20242024-12-31USD -4.89-20.9%
20252025-12-31USD -3.95-19.1%
Jasper Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3035.1%
Q42025-12-3171.7%
Q12026-03-3187.5%
Q22026-06-30-150.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$18.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$847.14K

N/A

Employees

22

N/A

Net Income

-$2.76M

+89.7%

EBITDA

-$2.76M

+89.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$7.31M

-81.5%

Total Debt

$270.00K

-87.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$270.00K

-86.2%

Return on Assets

-2.69%

N/A

Return on Invested Capital

-13.94%

N/A

Free Cash Flow

-$6.92M

+55.2%

Operating Cash Flow

-$6.92M

+55.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NXTCNextCure, Inc.
$6.37+11.96%
PSTVPlus Therapeutics, Inc.
$3.87-3.25%
BTAIBioXcel Therapeutics, Inc.
$0.07+64.22%
MURAMural Oncology plc
$2.04+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SXTCChina Sxt Pharmaceuticals
$5.39+331.20%
BULLWebull
$5.92-18.75%
INTCIntel
$113.26+0.67%
NOKNokia
$10.72-2.28%

Questions About JSPR

What is the current price of Jasper Therapeutics?

Jasper Therapeutics is trading at $0.57 per share.

What is the 52-week range for Jasper Therapeutics?

Over the past 52 weeks, Jasper Therapeutics has traded between $0.32 and $2.69.

How much debt does Jasper Therapeutics have?

As of the most recent reporting period, Jasper Therapeutics reported total debt of $270.00K.

How much cash does Jasper Therapeutics have on hand?

Jasper Therapeutics reported $7.73M in cash and cash equivalents in its most recent financial results.

What is Jasper Therapeutics’s dividend yield?

Jasper Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services